This trial will compare the effects of a new drug, obinutuzumab, to a placebo in people with active SLE. The trial will be double-blind, meaning neither the participants nor the researchers will know who is receiving the real drug or the placebo.
1 Primary · 20 Secondary · Reporting Duration: Up to approximately 6 years
Experimental Treatment
Non-Treatment Group
200 Total Participants · 2 Treatment Groups
Primary Treatment: Obinutuzumab · Has Placebo Group · Phase 3
Age 18 - 75 · All Participants · 7 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: